A review by two doctors in 2016 could find no double-blind clinical trials to measure whether taurine affects the energy of healthy human patients (though there are suggesting that taurine can improve cognitive performance in old age).

Source: https://www.theguardian.com/food/2023/feb/18/how-the-world-got-hopped-up-on-energy-drinks-prime-logan-paul-ksi

Both the induction and maintenance studies were randomized, double-blind, placebo-controlled, parallel group, multi-center studies.

Source: https://www.marketscreener.com/quote/stock/JOHNSON-JOHNSON-4832/news/Johnson-Johnson-New-STELARA-ustekinumab-Long-Term-Data-Support-its-Established-Safety-Profile-43156990/?utm_medium=RSS&utm_content=20230304

The study was conducted as a randomized, double-blind, dose-ranging, placebo-controlled to evaluate the safety, pharmacokinetics, and pharmacodynamic effects of OC514 in 28 healthy volunteers.

Source: https://www.ibtimes.com.au/press-release/20230511/oncocross-completes-phase-i-global-clinical-trial-of-oc514-treatment-for-sarcopenia

This trial is a randomized, double-blind, placebo-controlled, single ascending and multiple ascending dose study.

Source: https://seekingalpha.com/article/4576617-viking-therapeutics-inc-vktx-q4-2022-earnings-call-transcript?source=feed_all_articles